fda not allowing compounded semaglutide issued 25 warning letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have been proven to be safe, effective, or of FDA issues warning about some

The purity tests (HPCL assay showing 99% purity, etc) are testing ONLY the purity of the peptide portion of the total mix (which is very tiny)

It can be used as both injection-type or oral-type drug.[9] The marketing authorization in EU was granted on 8 February 2018.[10] It is still under review by regulatory authorities in Japan, pending approval.[11] ------------------------------------- Reported by Jules Levin AASLD 2018 Nov 9-13 SF Philip N Newsome1 ,2, Stephen A Harrison3, Sren Rasmussen4, Tea Monk Fries4, Luc Van Gaal5 1National Institute for Health Research Birmingham Biomedical Research Centre and Liver Unit at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

While semaglutide is considered to have an overall excellent safety profile, subjects with increased risk of the previously mentioned severe side effects are advised to exercise caution

Taking levothyroxine on a truly empty stomachbefore food and other medicationsremains the gold standard

1 reason for stopping GLP1s is financial, Hill said

Yes, it saved lives, but it didn't last very long, so you had to inject a lot of it very frequently